New company name for Special Products Ltd

2nd October 2017:

Weybridge, UK: Today, Veriton Pharma Ltd is announced as the new company name for Special Products Ltd.

This name change has occurred both to incorporate the company’s past heritage with its future ambitions to make trusted medicines available for everyday living.

The Chief Commercial Officer commented: “With the launch of Epistatus® 10mg in 1mL Oromucosal Solution Midazolam (as maleate), on the 8th of September 2017, and our extensive range of existing unlicensed medicines, we would like to assure our customers and partners that the excellent service and quality they have come to expect from us as a company will continue and all contacts at the company will remain the same.”

With its legacy of technical expertise, which began in a world-renowned children’s hospital over 20 years ago, Veriton Pharma sources and supplies licensed medicines for CNS and over 75 high-quality, UK batch manufactured unlicensed medicines in the fields of epilepsy, neurology and rare paediatric conditions that licensed products cannot meet.

Headquartered in Weybridge, UK, Veriton Pharma, is a privately owned, speciality pharmaceutical company, which also has regional offices in the Middle East and Australia.

For media enquiries please contact Helen Lawn & Associates. Telephone 01892 525141 / 07879 818247 or contact@helenlawn.co.uk

Notes to Editors:

For further information about Veriton Pharma, visit www.veritonpharma.com

For comment and interviews, please contact Helen Lawn & Associates Ltd.

Epistatus® prescribing information can be found here.

EDM/1036/2017

Date of preparation August 2017.

 

1st Saudi Metabolomics Symposium

18th – 19th February 2019 in Saudi Arabia

International, regional and local experts will be speaking on a range of topics covering the following symposium themes:

  • Basic Methodological Strategies in Metabolomics
  • Clinical Implications
  • Lipidomics
  • Novel Metabolic Diseases Phenomics
  • Glycomics
  • Clinical Implications in Inborn Error of Metabolism including Lysosomal Storage Diseases (MPS, Gaucher…), Amino-Acidopathy and Organic Academia
  • Metabolomics in Drug Discovery and Therapeutic Monitoring in LSD, Amino-Acidopathy & Organic Academia

Epistatus® 10 mg oromucosal solution midazolam – now available to prescribe

8th September 2017:

Special Products Ltd is pleased to announce that Epistatus® 10 mg Oromucosal Solution, Midazolam, is now available to prescribe.  The NHS price for a single 10mg in 1mL prefilled syringe is £45.76.

Epistatus® is licensed for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy1. Buccal midazolam is recommended by NICE2 for the management of prolonged acute convulsive seizures, and is preferred by most patients and carers compared to the administration of rectal diazepam 3,4.

Epistatus is presented “ready-to-use” in a novel, pre-filled, single-dose syringe, to provide carers with the confidence that they are administering the correct dose1,5. The pre-filled syringe is contained within a specially-designed, secure and tamper-evident protective packaging.

Dr Rohit Shankar FRCPsych, Consultant in Adult Developmental Neuropsychiatry – CFT and Hon. Associate Clinical Professor – Exeter Medical School commented: “The importance of having an alternate licensed preparation for use in the treatment of prolonged, acute convulsive seizures, especially in a different mode of delivery is an asset to both clinicians and patients”.

In response to market research and insights, Special Products Ltd has invested heavily in the development of this new bespoke syringe, which is designed to allow simple administration of the dose into the buccal cavity5.

Community Pharmacists can obtain Epistatus® 10mg/1mL pre-filled syringes exclusively via Alliance Healthcare.

Hospitals can order Epistatus® 10mg/1mL pre-filled syringes directly from Veriton Pharma www.veritonpharma.com

For further information on Epistatus 10 mg oromucosal midazolam pre-filled syringes, please visit www.epistatus.co.uk

For media enquiries or if you would like a packshot of Epistatus please contact Helen Lawn & Associates.  Telephone 01892 525141 / 07879 818247 or helen@helenlawn.co.uk

References:

  1. Epistatus 10mg oromucosal solution.  Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence (2012). The epilepsies: the diagnosis and management of epilepsies in adults and children in primary care. NICE clinical guideline CG 137.
  3. Nakken K and Lossius M. Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. Acta Neurol Scand: (2011); 124:99-103.
  4. Ashrafi MR et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. European Journal of Paediatric Neurology (2010); doi10.1016/j.ejpn.2010.05.009.
  5. Data on file – Excerpts from Epistatus Patent Application.

EDM/1037/2017

Date of preparation August 2017 

Epistatus® prescribing information can be found here.